Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for New Cancer Cure Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for New Cancer Cure Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About New Cancer Cure Bio
Developer of biopharmaceutical products designed to advance biotechnology research and therapeutic applications. The company develops recombinant proteins, monoclonal antibodies, and cell culture systems, conducts bioengineering and molecular biology research, provides contract manufacturing for clinical and commercial use, and maintains facilities for quality testing and regulatory compliance, enabling pharmaceutical companies, research institutions, and healthcare organizations to access reliable biologics, accelerate innovation, ensure safety standards, and support advanced medical treatments across diverse therapeutic areas.
- Sector
- Healthcare
- HQ
- Goyang, South Korea
- Founded
- 2020
- Employees
- 8
- Website
- nccbio.co.kr/
- Ownership
- Privately Held (backing)
New Cancer Cure Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in New Cancer Cure Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on New Cancer Cure Bio in its N-PORT filings yet. We sweep new filings monthly.